

عنوان مقاله:

Evaluation of commonly used drugs in patients with COVID-۱۹: A systematic review study

محل انتشار:

مجله سرطان شناسی و علوم پزشکی، دوره 1، شماره 2 (سال: 1400)

تعداد صفحات اصل مقاله: 10

نویسندگان:

Shahab Dastmardi - *Student Research Committee, School of Pharmacy, Guilan University of Medical Sciences, Rasht, Iran*

Parsa Monajemi - *Student Research Committee, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran*

Fatemeh Bakhtiari Hoshyar - *Student Research Committee, School of Pharmacy, Guilan University of Medical Sciences, Rasht, Iran*

Hossein Majidinia - *Family Medicine Specialist, Guilan University of Medical Sciences, Rasht, Iran*

Kourosh Delpasand - *Department of Medical Ethics, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran*

خلاصه مقاله:

Introduction: COVID disease is an infectious disease caused by coronavirus ۲ (SARS - CoV-۲) and causes severe acute respiratory syndrome in patients. From arrival to proliferation in the deep part of the lung can be classified into three stages. Most people get only a mild form of the disease, but up to ۲۰% of the virus may penetrate deep into the lungs and cause hypoxia and acute respiratory distress syndrome. This study provides an overview of the main treatment strategies that have been performed to date in randomized, clinical, and experimental controlled trials of COVID-۱۹ in pubmed and Google Scholar databases. From ۴۵۳ identified studies, after eliminating irrelevant and duplicate cases, ۶۴ clinical trials were selected to extract the data. And we examined the drugs that were most effective. Due to the clinical trials of drugs with different pharmacological properties, none of them have a definite effect on the treatment of Covid ۱۹ disease, and among them, only Ramdsavir and Barstenib are licensed for emergency use. Mulnipevirovir and Pexlovid have had good clinical trials but have not yet received final FDA approval.

کلمات کلیدی:

COVID ۱۹ , D rug, C linical trial

لینک ثابت مقاله در پایگاه سیویلیکا:

<https://civilica.com/doc/1546416>



